ISSN 2736-1748
African Journal of AIDS and HIV Research ISSN 2326-2691 Vol. 6 (1), pp. 322-324, January, 2018. © International Scholars Journals
Short Communication
A study of virologic and immunologic efficacy of a fixed dose combination of TDF 300 mg /emtricitabine
Markus Bickel*, Christoph Stephan, Tessa Lennemann, Pavel Khaykin, Gabi Nisius, Hans Reinhard Brodt, Schlomo Staszewski and Annette Haberl
HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany.
Accepted 19 August, 2017
Abstract
A randomized pilot-study to evaluate the virologic efficacy of Tenofovir-DF (TDF) 300 mg/Emtricitabine (FTC) 200 mg once daily plus Zidovudine (AZT) 250 mg twice daily (armA) or 300 mg BID (armB) in naïve HIV-1 infected patients. Twenty patients with a median CD4 cell count of 288 cells/µl (standard deviation (SD): ± 109) and a median viral load of 66.400 HIV RNA copies/ml (SD: ± 70.700) were included. Three patients in armA and one in armB had a single HIV-RNA-PCR measurement of > 50 copies/ml (p = 0.58). The combined median CD4 cells increased by 188 cells/µl at week 48. TDF 300 mg/FTC 200 mg once daily in combination with AZT 250 mg or 300 mg twice daily was well tolerated and no virologic failure occurred.
Key words: Class sparing, nucleoside reverse transcriptase inhibitor (NRTI), K65R, drug interaction.